Amgen Q3 FY26: where the revenue came from and where it went
The whole income statement of Amgen for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Nov 4, 2026
Revenue$10.4B
+8% year over year
Gross profit$7.6B
73% margin
Operating profit$3.7B
36% margin
Net profit$3.9B
37% margin
Net profit is larger than what operations earned, because the statement adds $1.0B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 10.4 | 100% | +8% |
| Other revenue | 4.5 | 43% | |
| Other products | 1.7 | 17% | |
| Repathaevolocumab | 1.1 | 11% | |
| Evenity | 0.8 | 7% | +39% |
| Prolia | 0.6 | 6% | −45% |
| Enbrel | 0.6 | 6% | +5% |
| Tezspire | 0.5 | 5% | |
| Tepezza | 0.5 | 5% | −6% |
| Cost of revenue | −2.8 | 27% | |
| Gross profit | 7.6 | 73% margin | +5pp |
| SG&A | −1.7 | 16% | −2pp |
| Other | −2.2 | 21% | |
| Operating profit | 3.7 | 36% margin | +9pp |
| Other income, net | 1.0 | ||
| Tax | −0.8 | ||
| Net profit | 3.9 | 37% margin | +4pp |
1 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest